DOCSLIB.ORG

Estrogen Receptor Regulates Insulin-Like Growth Factor-I Receptor Gene Expression in Breast Tumor Cells: Involvement of Transcription Factor Sp1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Estrogen Receptor Regulates Insulin-Like Growth Factor-I Receptor Gene Expression in Breast Tumor Cells: Involvement of Transcription Factor Sp1 605 Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1 Sharon Maor, Doris Mayer1, Ronit I Yarden2, Adrian V Lee3, Rive Sarfstein, Haim Werner and Moshe Z Papa4 Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel 1Group on Hormones and Signal Transduction, German Cancer Research Center, Heidelberg D-69120, Germany 2Laboratory of Genomic Applications, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel 3Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA 4Department of Oncological Surgery, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel (Requests for offprints should be addressed to H Werner; Email: [email protected]) Abstract The insulin-like growth factors, IGF-I and IGF-II are a familyof along with the Sp1-family-binding inhibitor Mithramycin A. mitogenic polypeptides with important roles in growth and The results obtained indicate that basal IGF-IR promoter differentiation. The biological actions of the IGFs are mediated activity was 5.8-fold higher in MCF-7 than in C4 cells. Estradiol by the IGF-I receptor (IGF-IR), a cell-surface tyrosine kinase, treatment significantly activated the IGF-IR promoter in whose activation by serum IGF-I seems to be a key step in breast MCF-7, but not in C4 cells. Furthermore, the estrogen cancer initiation. Evidence accumulated indicates that estrogens responsive region in the IGF-IR promoter was mapped to a stimulate the expression and activity of IGF axis components. GC-rich sequence located between nucleotides K40 and The aim of our study was to examine the transcriptional K188 in the 50 flanking region. ChIPexperiments revealed that mechanisms involved in regulation of IGF-IR gene expression at least part of the estrogen effect on IGF-IR expression was by the estrogen receptor (ER). For this purpose, transient mediated through activation of the Sp1 transcription factor. In transfections using an IGF-IR promoter-luciferase reporter summary, our studies demonstrate that IGF-IR gene transcrip- plasmid were performed in breast cancer-c derived ER-positive tion in breast cancer cells is controlled by interactions between MCF-7 cells and isogenic ER-negative C4 cells. Toexamine the ERa and Sp1. Dysregulated expression of the IGF-IR gene may potential involvement of zinc-finger nuclear proteins in the have pathologic consequences with relevance in breast cancer transactivating effect of estrogens, chromatin immunoprecipita- etiology. tion(ChIP) experimentswere performed using an Sp1 antibody, Journal of Endocrinology (2006) 191, 605–612 Introduction expressed in breast tumors, including ligands, receptors, and binding proteins (IGFBPs) (Ye e et al. 1989, Schnarr et al. The insulin-like growth factors, IGF-I and IGF-II, are a 2000, Surmacz 2000). The central role of the IGF-IR as a family of mitogenic polypeptides with important roles in mediator of both IGF-I and IGF-II action in breast cancer is growth and differentiation. The biological actions of the IGFs illustrated by the results of several groups showing that are mediated by the IGF-I receptor (IGF-IR), a trans- blockage of the IGF-IR by a variety of methods, including membrane tyrosine kinase structurally and evolutionarily anti-IGF-IR antibodies, antisense oligonucleotides against related to the insulin receptor (LeRoith et al. 1995, Baserga IGF-IR mRNA, and IGFBPs significantly inhibited cellular et al. 1997, Werner & LeRoith 2000). The IGF-IR axis has a proliferation (Arteaga et al. 1989, Van der Burg et al. 1990, central role in cell cycle progression, as demonstrated by the Surmacz et al. 1998). Further evidence in support of an fact that receptor overexpression in fibroblasts abrogates important role for the IGF system in breast carcinogenesis is all requirements for additional growth factors in order to also provided by epidemiological studies, showing a positive promote cellular proliferation (Pietrzkowski et al. 1992). correlation between circulating IGF-I concentrations and In addition, evidence is mounting for a pivotal role for the relative risk of breast cancer (Hankinson et al. 1998). IGF-IR in tumorigenesis (Werner & LeRoith 1996, Baserga Solid evidence accumulated in recent years indicating that 1999). Essentially, all components of the IGF system are the biological activity of the IGF system is strongly associated Journal of Endocrinology (2006) 191, 605–612 DOI: 10.1677/joe.1.07016 0022–0795/06/0191–605 q 2006 Society for Endocrinology Printed in Great Britain Online version via http://www.endocrinology-journals.org Downloaded from Bioscientifica.com at 09/28/2021 04:38:28AM via free access 606 SMAORand others . Regulation of IGF-IR gene expression by estrogen receptor with estrogen status (Lee et al. 1999, Yee & Lee 2000). Western immunoblots Estrogens were shown to increase IGF-I binding and IGF-IR Cells were serum-starved overnight and then incubated with mRNA levels in MCF-7 cells by sevenfold, suggesting that increasing concentrations of b-estradiol (Sigma-Aldrich Corp.) the potential mechanism by which estrogens stimulate breast for 24 h. Following incubation, cells were harvested and lysates cancer cell proliferation involves sensitization to the mitogenic effects of IGFs by enhancing IGF-IR concen- were prepared as described previously (Idelman et al. 2002). m tration (Stewart et al. 1990). In addition, estrogens can Samples (50 g) were subjected to 8% SDS-PAGE, followed by modulate IGF signaling by regulating the expression of other electrophoretic transfer of the proteins to nitrocellulose members of the IGF family, including ligands, IGFBPs, and membranes. After blocking with 3% bovine serum albumin or milk in T-TBS (20 mM Tris–HCl, pH 7.5, 135 mM NaCl, and insulin receptor substrate (IRS)-1 (Osborne et al. 1989, . McGuire et al. 1992, Salerno et al. 1999). Using MCF-7- 0 1% Tween-20), blots were incubated with polyclonal derived sublines that have been selected for loss of estrogen antibodies against IGF-IR b subunit, Sp1 and ERa (C-20, receptor a (ERa) by long-term estrogen withdrawal, it was PEP-2, and MC-20 respectively; Santa Cruz Biotechnology, previously demonstrated that the loss of ERa caused reduced Santa Cruz, CA, USA), and against actin or tubulin, followed by expression of IGF-signaling molecules and failure to incubation with a horseradish peroxidase-conjugated secondary proliferate in response to IGF-I or estrogen. Re-expression antibody. Proteins were detected using the SuperSignal West of ERa restored the IGF-responsive phenotype, suggesting Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA). that ERa is a crucial regulator of the IGF mitogenic loop In selected experiments, the Sp1-family inhibitor Mithramycin (Oesterreich et al. 2001). A (Sigma-Aldrich Corp.) was added at a concentration of The IGF-IR promoter is a TATA-less, CAAT-less, and 500 nM 1 h before the estradiol treatment. initiator type of promoter. The region flanking the transcription start site is extremely GC-rich, and contains IGF-IR promoter activity measurements numerous potential binding sites for transcription factor Sp1, a zinc-finger-containing nuclear protein that has been shown For transient transfection experiments, luciferase reporter K C K C to strongly transactivate the IGF-IR promoter (Beitner- constructs p( 2350/ 640)LUC, p( 476/ 640)LUC, K C K C Johnson et al. 1995). Given the involvement of ERa in p( 188/ 640)LUC, and p( 40/ 640)LUC (nucleotide 1 control of IGF-IR gene expression and IGF-I action, and in corresponds to the transcription start site) were employed. view of the fact that the transcriptional mechanisms involved These plasmids include 2350, 476, 188, or 40 nucleotides of the 0 0 in regulation of the IGF-IR gene by ERa have not yet been 5 -flanking region, linked to 640 bp of the 5 -untranslated characterized, the present study was designed to analyze region of the rat IGF-IR gene. The basal promoter activities of the molecular mechanisms responsible for regulation of the these constructs were previously reported (Maor et al. 2000). IGF-IR gene by ERa. Specifically, we hypothesized that ERa The ERa expression vector was generated by subcloning the regulates IGF-IR gene expression through interaction with human ERa cDNA into the pSG5 vector using EcoRI sites. transcription factor Sp1. The results obtained prove that ERa The ERa vector was provided by Dr Yitzhak Koch, Weizmann is a potent transactivator of the IGF-IR gene and that GC-rich Institute of Science, Rehovot, Israel. An Sp1 expression vector sequences in the proximal IGF-IR promoter region are (pPacSp1), under the control of an actin promoter in the pPac0 required for this effect. Impaired interactions between ERa vector, was provided by Dr Robert Tjian (University of and zinc-finger proteins may lead to aberrant IGF-IR California, Berkeley, CA, USA). Cells were seeded in six-well expression in breast cancer cells. plates 48 h before transfection, and transfected with 0.5 mgof the indicated IGF-IR promoter reporter plasmids, along with 1.3 mgERa expression vector (or empty pSG5 vector), 1 mg pPacSp1 (or empty pPac0 vector), and 0.2 mg b-galactosidase Materials and Methods expression plasmid (pCMVb,Clontech,PaloAlto,CA,USA), using the jetPEI reagent (Polyplus Transfection, Illkirch, Cell cultures France). Twenty-four hours after transfection, cells were treated The MCF-7 human breast cancer cell line was maintained in with estradiol (1, 10 and 100 nM) or left untreated. Cells were Dulbecco’s modified Eagle’s medium (DMEM) supplemented harvested after an additional 24 h, and luciferase and with 10% fetal bovine serum (FBS), 2 mM glutamine, and b-galactosidase activities were measured as previously described 50 mg/ml gentamicin sulfate. C4 cells were generated by clonal (Maor et al. 2000). In addition, some experiments included selection of MCF-7 cells, cultured in estrogen-free medium Mithramycin A.
Load more

Recommended publications
  • Analysis of Estrogen Receptor Isoforms and Variants in Breast Cancer Cell Lines
    EXPERIMENTAL AND THERAPEUTIC MeDICINE 2: 537-544, 2011 Analysis of estrogen receptor isoforms and variants in breast cancer cell lines MAIE AL-BADER1, CHRISTOPHER FORD2, BUSHRA AL-AYADHY3 and ISSAM FRANCIS3 Departments of 1Physiology, 2Surgery, and 3Pathology, Faculty of Medicine, Kuwait University, Safat 13110, Kuwait Received November 22, 2010; Accepted February 14, 2011 DOI: 10.3892/etm.2011.226 Abstract. In the present study, the expression of estrogen domain C, the DNA binding domain; domains D/E, bearing receptor (ER)α and ERβ isoforms in ER-positive (MCF7, both the activation function-2 (AF-2) and the ligand binding T-47D and ZR-75-1) and ER-negative (MDA-MB-231, SK-BR-3, domains; and finally, domain F, the C-terminal domain (6,7). MDA-MB-453 and HCC1954) breast cancer cell lines was The actions of estrogens are mediated by binding to ERs investigated. ERα mRNA was expressed in ER-positive and (ERα and/or ERβ). These receptors, which are co-expressed some ER-negative cell lines. ERα ∆3, ∆5 and ∆7 spliced in a number of tissues, form functional homodimers or variants were present in MCF7 and T-47D cells; ERα ∆5 heterodimers. When bound to estrogens as homodimers, the and ∆7 spliced variants were detected in ZR-75-1 cells. transcription of target genes is activated (8,9), while as heterodi- MDA-MB-231 and HCC1954 cells expressed ERα ∆5 and ∆7 mers, ERβ exhibits an inhibitory action on ERα-mediated gene spliced variants. The ERβ1 variant was expressed in all of the expression and, in many instances, opposes the actions of ERα cell lines and the ERβ2 variant in all of the ER-positive and (7,9).
    [Show full text]
  • Expression of Aromatase, Estrogen Receptor and , Androgen
    0031-3998/06/6006-0740 PEDIATRIC RESEARCH Vol. 60, No. 6, 2006 Copyright © 2006 International Pediatric Research Foundation, Inc. Printed in U.S.A. Expression of Aromatase, Estrogen Receptor ␣ and ␤, Androgen Receptor, and Cytochrome P-450scc in the Human Early Prepubertal Testis ESPERANZA B. BERENSZTEIN, MARI´A SONIA BAQUEDANO, CANDELA R. GONZALEZ, NORA I. SARACO, JORGE RODRIGUEZ, ROBERTO PONZIO, MARCO A. RIVAROLA, AND ALICIA BELGOROSKY Research Laboratory [E.B.B., M.S.B., C.R.G., N.I.S., J.R., M.A.R., A.B.], Hospital de Pediatria Garrahan, Buenos Aires C124 5AAM, Argentina; Centro de Investigaciones en Reproduccion [R.P.], Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires C112 1ABG, Argentina ABSTRACT: The expression of aromatase, estrogen receptor ␣ might affect adult testicular cell mass, as well as testicular (ER␣) and ␤ (ER␤), androgen receptor (AR), and cytochrome P-450 function (8). side chain cleavage enzyme (cP450scc) was studied in prepubertal In humans (9), there are three growth phases of LCs testis. Samples were divided in three age groups (GRs): GR1, during testicular development. Fetal LCs produce testoster- ϭ newborns (1- to 21-d-old neonates, n 5); GR2, postnatal activation one required for fetal masculinization and Insl-3, necessary ϭ stage (1- to 7-mo-old infants, n 6); GR3, childhood (12- to for testicular descent (10). They regress during the third ϭ ␣ 60-mo-old boys, n 4). Absent or very poor detection of ER by trimester of pregnancy. A second wave of infantile LCs has immunohistochemistry in all cells and by mRNA expression was been described during the postnatal surge of luteinizing observed.
    [Show full text]
  • Expression of Estrogen Receptor-Beta Isoforms in Barrett's
    ANTICANCER RESEARCH 24: 2919-2924 (2004) Expression of Estrogen Receptor-Beta Isoforms in Barrett’s Metaplasia, Dysplasia and Esophageal Adenocarcinoma LIANG LIU, MINNI CHIRALA and MAMOUN YOUNES Departments of Pathology, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, U.S.A. Abstract. We have previously shown that the majority of and beta (ER-B). ER-A is mainly expressed in female sex esophageal adenocarcinomas (EA), and its precursor Barrett’s organs, such as breast and uterus (2), whereas ER-B is metaplasia (BM), express estrogen receptor beta (ER-B). Several expressed in both sex organs and other tissues, such as isoforms of ER-B have been described and are presumed to have prostate, lung, thyroid, adrenal cortex and testis (3). Several different functions, but their distribution in BM and EA is not ER-B isoforms have been identified and characterized in known. The aim of this work was to determine which ER-B many non-gynecologic tumors including carcinomas of the isoforms are expressed in EA and BM. Sections of formalin-fixed lung (4), prostate (5), colon (6, 7) and stomach (8). and paraffin-embedded esophageal tissue from 33 esophageactomy Tamoxifen, a specific ER-B antagonist, has been successfully specimens, of which 27 had invasive EA, were stained for the ER- used in the treatment of patients with breast carcinoma B isoforms ER-B1, ER-B2, ER-B3 and ER-B5 utilizing the (9,10) and it has been shown that ER-B status is a significant immunoperoxidase method. ER-B1 was detected in 23 out of 27 predictor of survival in women with breast carcinoma treated (85%) EA compared to 3 out of 14 (21%) Barrett’s metaplasia with mastectomy and adjuvant tamoxifen (11).
    [Show full text]
  • Estrogen-Related Receptor Alpha: an Under-Appreciated Potential Target for the Treatment of Metabolic Diseases
    International Journal of Molecular Sciences Review Estrogen-Related Receptor Alpha: An Under-Appreciated Potential Target for the Treatment of Metabolic Diseases Madhulika Tripathi, Paul Michael Yen and Brijesh Kumar Singh * Laboratory of Hormonal Regulation, Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School, Singapore 169857, Singapore; [email protected] (M.T.); [email protected] (P.M.Y.) * Correspondence: [email protected] Received: 7 February 2020; Accepted: 24 February 2020; Published: 28 February 2020 Abstract: The estrogen-related receptor alpha (ESRRA) is an orphan nuclear receptor (NR) that significantly influences cellular metabolism. ESRRA is predominantly expressed in metabolically-active tissues and regulates the transcription of metabolic genes, including those involved in mitochondrial turnover and autophagy. Although ESRRA activity is well-characterized in several types of cancer, recent reports suggest that it also has an important role in metabolic diseases. This minireview focuses on the regulation of cellular metabolism and function by ESRRA and its potential as a target for the treatment of metabolic disorders. Keywords: estrogen-related receptor alpha; mitophagy; mitochondrial turnover; metabolic diseases; non-alcoholic fatty liver disease (NAFLD); adipogenesis; adaptive thermogenesis 1. Introduction When the estrogen-related receptor alpha (ESRRA) was first cloned, it was found to be a nuclear receptor (NR) that had DNA sequence homology to the estrogen receptor alpha (ESR1) [1]. There are several examples of estrogen-related receptor (ESRR) and estrogen-signaling cross-talk via mutual transcriptional regulation or reciprocal binding to each other’s response elements of common target genes in a context-specific manner [2,3].
    [Show full text]
  • TF Activation Profiling Plate Array II Signosis, Inc
    Signosis, Inc. Innovative Plate Assay Solutions TF Activation Profiling Plate Array II Catalog Number: FA-1002 (For Research Use Only) Introduction Materials Provided with the Kit Transcription factors (TFs) are a group of cellular proteins that play essential roles in regulating gene Component Qty Store at expression. They act as sensors to monitor cellular 96-Well Plates (with 2 RT changes and convert signals into gene expression. aluminum adhesive seal) Often, a specific cellular signal pathway can activate Isolation Columns 2 RT multiple TFs. The expression of a specific gene can Elution Buffer 400µL RT also be under the control of multiple TFs. Thus, TF Plate Hybridization Buffer 20mL RT monitoring the activation of multiple TFs 5X Plate Hybridization Wash 60mL RT simultaneously is critical to understanding the Buffer molecular mechanism of cellular regulation underlying 5X Detection Wash Buffer 60mL RT cell signaling and gene expression. Signosis, Inc.’s TF Blocking Buffer 60mL RT Activation Profiling Plate Array II is used for Filter Wash Buffer 5mL 4°C monitoring 96 different TFs simultaneously from one Filter Binding Buffer 1mL 4°C sample. Substrate A 2mL 4°C Substrate B 2mL 4°C Principle of the assay Streptavidin-HRP Conjugate 40µL 4°C Substrate Dilution Buffer 16mL 4°C Signosis, Inc.’s TF Activation Profiling Plate Array II TF Binding Buffer Mix 60µL -20°C is used for monitoring the activation of multiple TFs TF Probe Mix II 20µL -20°C simultaneously. With this technology a series of biotin-labeled probes are made based on the consensus sequences of TF DNA-binding sites.
    [Show full text]
  • Interindividual Regulation of the BCRP/ABCG2 Transporter in Term Human Placentas
    DMD Fast Forward. Published on January 31, 2018 as DOI: 10.1124/dmd.117.079228 This article has not been copyedited and formatted. The final version may differ from this version. DMD #79228 Title Page Interindividual Regulation of the BCRP/ABCG2 Transporter in Term Human Placentas Kristin M Bircsak, Jamie E Moscovitz, Xia Wen, Faith Archer, Poi Yu Sofia Yuen, Moiz Mohammed, Naureen Memon, Barry I Weinberger, Laura M Saba, Anna M Vetrano, Lauren M Aleksunes Downloaded from Department of Pharmacology and Toxicology, Rutgers, The State University of New Jersey, Ernest Mario School of Pharmacy, Piscataway, NJ, USA (K.M.B., J.E.M., X.W., L.M.A.), dmd.aspetjournals.org Department of Pediatrics, Rutgers University Robert Wood Johnson Medical School, New Brunswick, NJ, USA (F.A., P.Y.S.Y, M.M., N.M., A.M.V.), Hofstra Northwell School of Medicine, Cohen Children’s Medical Center of New York, New Hyde Park, NY, USA (B.I.W.), at ASPET Journals on October 2, 2021 Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA (L.S.), Environmental and Occupational Health Sciences Institute, Rutgers, The State University of New Jersey, Piscataway, NJ, USA (L.M.A.), Lipid Center, Rutgers, The State University of New Jersey, Piscataway, NJ, USA (L.M.A.) 1 DMD Fast Forward. Published on January 31, 2018 as DOI: 10.1124/dmd.117.079228 This article has not been copyedited and formatted. The final version may differ from this version. DMD #79228 Running Title Page Running title: Interindividual
    [Show full text]
  • Therapeutic Targeting of the IGF Axis
    cells Review Therapeutic Targeting of the IGF Axis Eliot Osher and Valentine M. Macaulay * Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK * Correspondence: [email protected]; Tel.: +44-1865617337 Received: 8 July 2019; Accepted: 9 August 2019; Published: 14 August 2019 Abstract: The insulin like growth factor (IGF) axis plays a fundamental role in normal growth and development, and when deregulated makes an important contribution to disease. Here, we review the functions mediated by ligand-induced IGF axis activation, and discuss the evidence for the involvement of IGF signaling in the pathogenesis of cancer, endocrine disorders including acromegaly, diabetes and thyroid eye disease, skin diseases such as acne and psoriasis, and the frailty that accompanies aging. We discuss the use of IGF axis inhibitors, focusing on the different approaches that have been taken to develop effective and tolerable ways to block this important signaling pathway. We outline the advantages and disadvantages of each approach, and discuss progress in evaluating these agents, including factors that contributed to the failure of many of these novel therapeutics in early phase cancer trials. Finally, we summarize grounds for cautious optimism for ongoing and future studies of IGF blockade in cancer and non-malignant disorders including thyroid eye disease and aging. Keywords: IGF; type 1 IGF receptor; IGF-1R; cancer; acromegaly; ophthalmopathy; IGF inhibitor 1. Introduction Insulin like growth factors (IGFs) are small (~7.5 kDa) ligands that play a critical role in many biological processes including proliferation and protection from apoptosis and normal somatic growth and development [1]. IGFs are members of a ligand family that includes insulin, a dipeptide comprised of A and B chains linked via two disulfide bonds, with a third disulfide linkage within the A chain.
    [Show full text]
  • Common Single-Nucleotide Polymorphisms in the Estrogen Receptor B Promoter Are Associated with Colorectal Cancer Survival in Postmenopausal Women
    Published OnlineFirst November 13, 2012; DOI: 10.1158/0008-5472.CAN-12-2484 Cancer Prevention and Epidemiology Research Common Single-Nucleotide Polymorphisms in the Estrogen Receptor b Promoter Are Associated with Colorectal Cancer Survival in Postmenopausal Women Michael N. Passarelli1,2, Amanda I. Phipps1, John D. Potter1,2,3, Karen W. Makar1, Anna E. Coghill1,2, Karen J. Wernli3,4, Emily White1,2, Andrew T. Chan5,6, Carolyn M. Hutter1,2, Ulrike Peters1,2, and Polly A. Newcomb1,2 Abstract Loss of estrogen receptor b (ERb) expression in the gut is associated with colorectal cancer (CRC) initiation and progression. Germline single-nucleotide polymorphisms (SNP) in genes for the sex-steroid hormone receptors are not strongly associated with CRC risk; however, these SNPs have not previously been evaluated in relation to survival after diagnosis. We enrolled 729 women, ages 50 to 74, diagnosed with invasive CRC between 1997 and 2002 in 13 counties covered by the Seattle-Puget Sound Surveillance Epidemiology and End Results cancer registry. Participants provided germline DNA. We selected 99 tag-SNPs for the androgen receptor (AR), ERa (ESR1), ERb (ESR2), and progesterone receptor (PGR) genes. Mortality outcomes were ascertained from the National Death Index. During a median of 6.6 years of follow-up, 244 deaths occurred (161 from CRC). We identified 20 SNPs (12 of ESR2 and 8 of PGR) for replication in 1,729 women diagnosed with incident invasive CRC (555 deaths; 405 from CRC) from three prospective cohort studies that participate in the Genetics and Epidemiology of Colorectal Cancer Consortium. Three correlated SNPs in the promoter of ESR2 (rs2987983, rs3020443, and rs2978381) were statistically significant predictors of CRC-specific and overall survival.
    [Show full text]
  • A Dissertation Entitled the Androgen Receptor
    A Dissertation entitled The Androgen Receptor as a Transcriptional Co-activator: Implications in the Growth and Progression of Prostate Cancer By Mesfin Gonit Submitted to the Graduate Faculty as partial fulfillment of the requirements for the PhD Degree in Biomedical science Dr. Manohar Ratnam, Committee Chair Dr. Lirim Shemshedini, Committee Member Dr. Robert Trumbly, Committee Member Dr. Edwin Sanchez, Committee Member Dr. Beata Lecka -Czernik, Committee Member Dr. Patricia R. Komuniecki, Dean College of Graduate Studies The University of Toledo August 2011 Copyright 2011, Mesfin Gonit This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of The Androgen Receptor as a Transcriptional Co-activator: Implications in the Growth and Progression of Prostate Cancer By Mesfin Gonit As partial fulfillment of the requirements for the PhD Degree in Biomedical science The University of Toledo August 2011 Prostate cancer depends on the androgen receptor (AR) for growth and survival even in the absence of androgen. In the classical models of gene activation by AR, ligand activated AR signals through binding to the androgen response elements (AREs) in the target gene promoter/enhancer. In the present study the role of AREs in the androgen- independent transcriptional signaling was investigated using LP50 cells, derived from parental LNCaP cells through extended passage in vitro. LP50 cells reflected the signature gene overexpression profile of advanced clinical prostate tumors. The growth of LP50 cells was profoundly dependent on nuclear localized AR but was independent of androgen. Nevertheless, in these cells AR was unable to bind to AREs in the absence of androgen.
    [Show full text]
  • Supplemental Table 1. Primers and Probes for RT-Pcrs
    Supplemental Table 1. Primers and probes for RT-PCRs Gene Direction Sequence Quantitative RT-PCR E2F1 Forward Primer 5’-GGA TTT CAC ACC TTT TCC TGG AT-3’ Reverse Primer 5’-CCT GGA AAC TGA CCA TCA GTA CCT-3’ Probe 5’-FAM-CGA GCT GGC CCA CTG CTC TCG-TAMRA-3' E2F2 Forward Primer 5'-TCC CAA TCC CCT CCA GAT C-3' Reverse Primer 5'-CAA GTT GTG CGA TGC CTG C-3' Probe 5' -FAM-TCC TTT TGG CCG GCA GCC G-TAMRA-3' E2F3a Forward Primer 5’-TTT AAA CCA TCT GAG AGG TAC TGA TGA-3’ Reverse Primer 5’-CGG CCC TCC GGC AA-3’ Probe 5’-FAM-CGC TTT CTC CTA GCT CCA GCC TTC G-TAMRA-3’ E2F3b Forward Primer 5’-TTT AAA CCA TCT GAG AGG TAC TGA TGA-3’ Reverse Primer 5’-CCC TTA CAG CAG CAG GCA A-3’ Probe 5’-FAM-CGC TTT CTC CTA GCT CCA GCC TTC G-TAMRA-3’ IRF-1 Forward Primer 5’-TTT GTA TCG GCC TGT GTG AAT G-3’ Reverse Primer 5’-AAG CAT GGC TGG GAC ATC A-3’ Probe 5’-FAM-CAG CTC CGG AAC AAA CAG GCA TCC TT-TAMRA-3' IRF-2 Forward Primer 5'-CGC CCC TCG GCA CTC T-3' Reverse Primer 5'-TCT TCC TAT GCA GAA AGC GAA AC-3' Probe 5'-FAM-TTC ATC GCT GGG CAC ACT ATC AGT-TAMRA-3' TBP Forward Primer 5’-CAC GAA CCA CGG CAC TGA TT-3’ Reverse Primer 5’-TTT TCT TGC TGC CAG TCT GGA C-3’ Probe 5’-FAM-TGT GCA CAG GAG CCA AGA GTG AAG A-BHQ1-3’ Primers and Probes for quantitative RT-PCRs were designed using the computer program “Primer Express” (Applied Biosystems, Foster City, CA, USA).
    [Show full text]
  • Co-Targeting HER2/Erbb2 and Insulin-Like Growth Factor-1
    Signature: Med Sci Monit, 2002; 8(12): BR521-526 WWW.MEDSCIMONIT.COM PMID: 12503030 Basic Research Received: 2002.11.08 Accepted: 2002.11.20 Co-targeting HER2/ErbB2 and insulin-like growth BR Published: 2002.12.27 factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells Authors’ Contribution: A Study Design abcdef b AG B Data Collection Anne Camirand , Yuhong Lu , Michael Pollak C Statistical Analysis D Data Interpretation Department of Oncology, McGill University, Montréal, QC, Canada E Manuscript Preparation F Literature Search Source of support: Streams of Excellence program of the Canadian Breast Cancer Research Institute. G Funds Collection Summary Background: The humanized anti-HER2 monoclonal antibody trastuzumab (Herceptin®) is useful in the treatment of ErbB2-overexpressing breast cancers, but its efficiency is limited because devel- opment of resistance is common. In order to study the possibility of improving the efficacy of therapies directed against HER2/erbB2, we investigated the effects of co-targeting this recep- tor and the insulin-like growth factor 1 receptor (IGF-1R), a widely-expressed protein tyro- sine kinase with important roles in suppression of apoptosis and stimulation of proliferation. Material/Methods: The experimental strategy involved combining trastuzumab treatment and reduction of IGF- 1R signaling through incremental heat-induced expression of the dominant-negative IGF-1 receptor 486/STOP under the control of the heat-sensitive Drosophila HSP70 promoter, in HER2/erbB2-overexpressing MCF7her18 breast cancer cells. Results: Isobologram analysis of combinatorial treatment data revealed a strong synergistic interaction between trastuzumab treatment and the induction of the dominant-negative IGF-1R expres- sion, resulting in potentiation of growth inhibition in transfected cancer cells.
    [Show full text]
  • The Role of Constitutive Androstane Receptor and Estrogen Sulfotransferase in Energy Homeostasis
    THE ROLE OF CONSTITUTIVE ANDROSTANE RECEPTOR AND ESTROGEN SULFOTRANSFERASE IN ENERGY HOMEOSTASIS by Jie Gao Bachelor of Engineering, China Pharmaceutical University, 1999 Master of Science, China Pharmaceutical University, 2002 Submitted to the Graduate Faculty of School of Pharmacy in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2012 UNIVERSITY OF PITTSBURGH School of Pharmacy This dissertation was presented by Jie Gao It was defended on January 18, 2012 and approved by Billy W. Day, Professor, Pharmaceutical Sciences Donald B. DeFranco, Professor, Pharmacology & Chemical Biology Samuel M. Poloyac, Associate Professor, Pharmaceutical Sciences Song Li, Associate Professor, Pharmaceutical Sciences Dissertation Advisor: Wen Xie, Professor, Pharmaceutical Sciences ii Copyright © by Jie Gao 2012 iii THE ROLE OF CONSTITUTIVE ANDROSTANE RECEPTOR AND ESTROGEN SULFOTRANSFERASE IN ENERGY HOMEOSTASIS Jie Gao, PhD University of Pittsburgh, 2012 Obesity and type 2 diabetes are related metabolic disorders of high prevalence. The constitutive androstane receptor (CAR) was initially characterized as a xenobiotic receptor regulating the responses of mammals to xenotoxicants. In this study, I have uncovered an unexpected role of CAR in preventing obesity and alleviating type 2 diabetes. Activation of CAR prevented obesity and improved insulin sensitivity in both the HFD-induced type 2 diabetic model and the ob/ob mice. In contrast, CAR null mice maintained on a chow diet showed spontaneous insulin insensitivity. The metabolic benefits of CAR activation may have resulted from inhibition of hepatic lipogenesis and gluconeogenesis. The molecular mechanism through which CAR activation suppressed hepatic gluconeogenesis might be mediated via peroxisome proliferator- activated receptor gamma coactivator-1 alpha (PGC-1α).
    [Show full text]